
|Videos|May 29, 2013
The 340B Drug Discount Program
Adam J. Fein describes how the 340B program is being exploited by many hospital systems due to a lack of oversight by government agencies.
Advertisement
In this video, Adam J. Fein describes how the 340B program is being exploited by many hospital systems due to a lack of oversight by government agencies.
For more information about Dr. Fein's controversial op-ed on 340B pricing, see
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma
2
US Measles Cases Climb, Raising Questions About Preparedness and Prevention
3
Soaring off the Patent Cliff: Preparing for the Next Wave of Oncology Biosimilars
4
FDA Approves Depemokimab as Add-On Maintenance Treatment in Severe Asthma
5












































































































































































































